The MR-linac allows treatment plan adaption to the patient's daily anatomy – but how can we tell whether the new plan is suitable for delivery?
Read article: Software offers ‘sanity check’ for adapted plans in MR-guided radiotherapy
The first prospective study of MR-guided hypofractionated radiotherapy in prostate cancer patients demonstrates particularly low toxicity
Read article: MRI guidance minimizes toxicity in prostate cancer radiotherapy
At the ASTRO Annual Meeting, researchers unveil the latest research in areas such as cardiac radioablation, immunotherapy and machine learning
Read article: ASTRO: highlighting radiation oncology breakthroughs
Standard Imaging’s Adaptivo software tracks and reports the dosimetric impact of changes in patient anatomy and positioning during the course of radiation treatment
Read article: Dosimetry software captures daily, cumulative patient trends
Motion synchronization, adaptive planning and treatment versatility will unlock the full potential of hypofractionated radiotherapy for value-based cancer care
Read article: Hypofractionation: a new value proposition in radiation oncology
The PERTAIN trial is examining the impact of FDG PET/CT-guided chemoradiotherapy for lung cancer patients in low- and middle-income countries
Read article: PET/CT-guided chemoradiotherapy improves lung cancer outcomes
A $2.03 million grant will help researchers develop optical technologies to monitor treatment response during head-and-neck cancer therapy
Read article: Optical imaging to monitor cancer response early in the treatment process
Auto-generated radiotherapy plans reduce plan preparation time, decrease plan variation and improve healthy tissue sparing
Read article: Automated radiotherapy planning benefits clinicians and patients
A round-up of some recent international patent applications in radiation therapy
Read article: Innovation: patent applications review
Could irradiation at ultrahigh dose rates provide the next leap forward in cancer therapy?
Read article: FLASH radiotherapy: from preclinical promise to the first human treatment
